J&J Medical Connect
TECVAYLI®

(teclistamab-cqyv)

+ Save link
J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TECVAYLI® (teclistamab-cqyv)

Medical Information

TECVAYLI - Preparation and Administration Using Aseptic Technique in Clinical Trials

Last Updated: 08/06/2025

SUMMARY

  • Aseptic technique should be used to prepare and administer TECVAYLI.1  
  • In clinical trials, TECVAYLI was prepared using aseptic technique. It was preferred that the preparation of the product be performed under a laminar flow hood or biosafety cabinet.2 

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 04 August 2025.

 

References

Show
1 Data on File. Teclistamab. Company Core Data Sheet. Janssen Research & Development, LLC. EDMS-RIM-378072; version 008; 2024.  
2 Data on File. Investigational Product Preparation and Administration Instructions for Subcutaneous Administration of 10 mg/mL and 90 mg/mL Teclistamab (JNJ-64007957) by Weight Based Dosing in mg/kg. TV-TEC-208759; version 6.0; 2024.